Stock Analysis
Zimmer Biomet Holdings, Inc.ZBH
P/E 22.46×· 5Y range 19.89–129.18×· bottom 14% of history
Sector: Healthcare · Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
AnalystsHold33 analystsP/E 22.5× sits at the 14th percentile of its 5.086926762491444-year history.
Cash covers 6% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Quality77
- Growth71
Risks
- Profitability35
Mixed business trading cheap — priced for skepticism.
Bull Case
- ✓P/E 22.5× at bottom 14% of 5-year history
What's happening with ZBH
Profile
Strong valuation and earnings quality; profitability lags behind.
How is each axis scored?
- Valuation82/100 · Strong
- P/E vs own history (14th pct)25/25
- FCF yield (8.5%)25/25
- P/S (2.1x)20/25
- EV/EBIT (20.8x)12/25
- Growth71/100 · Moderate
- Revenue CAGR (1.2%)6/25
- Net income CAGR (15.1%)20/25
- EPS CAGR 5Y (16.8%)20/25
- Fwd implied growth (111.6%)25/25
- Profitability35/100 · Weak
- ROIC (4.8%)5/25
- ROE (6.4%)5/25
- Net margin (9.5%)13/25
- Operating margin (14.2%)12/25
- Financial Health51/100 · Moderate
- Altman Z (2.21)18/25
- Current ratio (1.69)18/25
- Interest coverage (3.7x)10/25
- Net cash / debt (D/A 31%)5/25
- Quality77/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.66)25/25
- FCF conversion (189%)25/25
- Margin stability (σ 9.4%)12/25
- Moat55/100 · Moderate
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (71.1%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -4.8%)5/25
Risk Flags
- ⚠2 loss-making years in recent history
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. Show more
With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Headquarters: WARSAW, IN · Employees: 17,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
82AP/E (TTM)22.3xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 19.9x–129.2x · 14th pct
P/FCF16.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield8.5%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.4%–9.4% · 95th pct
P/S (TTM)2.11xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.9x–4.3x · 7th pct
EV/EBIT20.8xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 17.5x–46.3x · 31st pct
EV/Sales2.9xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E10.5xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.42xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio4.24D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.05%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio23.4%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
35DROIC4.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE6.4%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA3.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin9.5%C
Grade C: AverageNet Income / Revenue
Operating Margin14.2%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin69.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin17.9%A
Grade A: HighFCF / Revenue
True FCF Margin16.7%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
71B+Revenue CAGR1.2%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR15.1%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)16.8%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth111.6%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-9.3%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income12.2%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.2%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
51CAltman Z-Score2.21C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.69xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.72xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.7xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment4.7yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT5.9xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.60xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.06xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
77B+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.66A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion188.8%A
Grade A: StrongFCF / Net Income
Margin Stability9.4%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue2.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.37xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Campbell Gary Craig Filed | Campbell Gary Craig | Option exercise | -1218 | |
Campbell Gary Craig Filed | Campbell Gary Craig | Option exercise | -2368 | |
Campbell Gary Craig Filed | Campbell Gary Craig | Tax withholding | -480 | |
Campbell Gary Craig Filed | Campbell Gary Craig | Option exercise | +1.2K | |
Campbell Gary Craig Filed | Campbell Gary Craig | Tax withholding | -932 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Campbell Gary Craig Filed | Campbell Gary Craig | Option exercise | +2.4K | |
Shapiro Louis Filed | Shapiro Louis | Grant / award | +153 | |
Kurdikar Devdatt Filed | Kurdikar Devdatt | Grant / award | +174 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
55CROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)71.1%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-4.8%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$4.23
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.15
Cash & short-term investments per share (Finnhub)
Book Value / Share$66.23
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$7.60B
Total debt obligations (short + long term)
Cash & Equiv.$464.50M
Cash and short-term investments
Net Debt$7.14B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$12.63B
Shareholders' equity (book value)
Asset / Liability2.24xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$17.98B
Current Market Capitalization
Beta0.49B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Zimmer Biomet Holdings, Inc. (ZBH)
ZBH is up 0.64% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Zimmer Biomet Holdings, Inc.. Altman Z-Score of 2.21 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.66 suggests a low likelihood of earnings manipulation.
- Zimmer Biomet Holdings, Inc. converts about 18% of revenue into free cash flow — strong cash generation.
- Takes ~4.7 years to repay net debt from free cash flow.
- Zimmer Biomet Holdings, Inc. posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 82/100, ZBH trades near the cheapest end of its own historical range (P/E 22.3).
See how ZBH ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ZBH moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 12 | After-hours | 92.17 | +3.40% | 2.17 |
| Oct 5 | Regular | 91.65 | +3.80% | 2.27 |
| Oct 5 | After-hours | 91.57 | +3.72% | 2.23 |
| Sep 23 | Regular | 90.28 | -3.94% | -2.15 |
Frequently Asked Questions about ZBH
What is the current Zimmer Biomet Holdings, Inc. (ZBH) stock price?
ZBH is trading at $94.98 at the last market close, up 0.64% on the session. PreMarketPrice tracks ZBH pre-market, intraday and after-hours prices.
Is ZBH stock a buy right now?
PreMarketPrice's quantitative model rates Zimmer Biomet Holdings, Inc.'s financial health at 51/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ZBH stock overvalued?
Zimmer Biomet Holdings, Inc. trades at a trailing P/E of 22.3 and our valuation score rates it 82/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Zimmer Biomet Holdings, Inc. report earnings?
No confirmed earnings date is currently scheduled for ZBH. The Earnings section lists recent reports and updates as dates are announced.
What sector does Zimmer Biomet Holdings, Inc. operate in?
Zimmer Biomet Holdings, Inc. operates in the Healthcare sector, within the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry. The Related Stocks section lists sector peers for comparison.
What does Zimmer Biomet Holdings, Inc. do?
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery.
About Zimmer Biomet Holdings, Inc. (ZBH) Stock
Zimmer Biomet Holdings, Inc. (ZBH) is a US-listed stock operating in the Healthcare sector, specifically the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry. As of the latest update, Zimmer Biomet Holdings, Inc. is trading at $94.98, up 0.64% on the day with a market capitalization of $18.0 billion. The financial health score for ZBH is 51/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ZBH stock.
ZBH Stock Analysis & Key Metrics
On PreMarketPrice, you can track Zimmer Biomet Holdings, Inc. (ZBH) across multiple dimensions:
- Pre-market price & movement: Real-time ZBH stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ZBH with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Zimmer Biomet Holdings, Inc. across multiple reporting periods.
- Financial health score: A composite score of 51/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ZBH.
- Sector peers: Compare ZBH against 6 other healthcare stocks on key financial metrics.
Is ZBH a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Zimmer Biomet Holdings, Inc. (ZBH) as an investment. The financial health score of 51/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Zimmer Biomet Holdings, Inc. (ZBH) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.